TSXV:CLAS.H - Post by User
Comment by
AngelaLon Jan 31, 2021 3:34am
183 Views
Post# 32430586
RE:RE:RE:RE:RE:RE:RE:Soon
RE:RE:RE:RE:RE:RE:RE:SoonBoth Novavax and J&J reported disappointing results from their vaccine trials. In the case of Novavax, they only showed 60% efficacy in their South African trial due to the poor performance against the mutant strain that is prevalent there (and has now spread globally). J&J did even worse, showing 65% protection against the non-mutant strains. Bottom line, not one of the vaccines available today is highly protective against the mutant strains. And new mutant strains are appearing weekly! I have high hopes that R-107 can fill the gap. Kalytera looks set to hit it out of the park given its positioning as the only nitric oxide therapy that can treat COVID throughout the whole body.